Search results for: Matthias Hofer
Filter search results
Matthias Hofer
5 April 2023
Matthias is a Principal Economist at OHE. His expertise and research interests include regulatory science and policy, the value of pharmaceuticals for patients and society, and the economics of pharmaceutical…
OHE at ISPOR 2024
5 May 2024, 12:00am
…fit for purpose? Grace Hampson & Matthias Hofer 07 May 2024 13:45 – 14:45 EDT Podium Session How elastic is biopharmaceutical innovation with respect to expected reward? What is missing…
Innovation for Health System Efficiency and Improvement
20 November 2023
Share this: Download publication Margherita Neri Matthias Hofer Fred McElwee Jia Pan Graham Cookson In this report, commissioned and funded by Gilead, we explore the role of innovation in developing…
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
Share this: Download publication Matthias Hofer Grace Hampson NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently…
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
Share this: Download publication Matthias Hofer Grace Hampson New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to…
Insights and Reflections from 2023
31 January 2024, 3:00pm
…lead the field in 2024. Speakers Graham Cookson Chief Executive Grace Hampson Director Chris Skedgel Director Amanda Cole Director Matthias Hofer Principal Economist Martina Garau Director Watch on demand https://player.vimeo.com/video/907466181…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Share this: Download publication Matthew Napier Brittany Darrow Matthias Hofer Mikel Berdud Amanda Cole Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Share this: Download publication Hania El Banhawi Henry Fong Matthias Hofer Lotte Steuten Compared to shorter acting therapies, long-acting therapies might be overlooked and hold potential for patients, healthcare systems…
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Share this: Download publication Claud Theakston Matthias Hofer Martina Garau Lotte Steuten Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies…